UY28631A1 - Uso extendido de combinación que comprende estrógenos y progestinas. - Google Patents

Uso extendido de combinación que comprende estrógenos y progestinas.

Info

Publication number
UY28631A1
UY28631A1 UY28631A UY28631A UY28631A1 UY 28631 A1 UY28631 A1 UY 28631A1 UY 28631 A UY28631 A UY 28631A UY 28631 A UY28631 A UY 28631A UY 28631 A1 UY28631 A1 UY 28631A1
Authority
UY
Uruguay
Prior art keywords
stratens
progestines
combination
extended use
progestin
Prior art date
Application number
UY28631A
Other languages
English (en)
Inventor
Bernd Dusterberg
Jan Endrikat
Rolf Schurmann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34443011&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28631(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY28631A1 publication Critical patent/UY28631A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una preparación farmacéutica para obtener un tratamiento hormonal continuo durante un período de tiempo deseado más prolongado que 21-28 días, que comprende una primera composición que contienen al menos un estrógeno y/o al menos una progestina en una cantidad predeterminada, que se administra en los primeros 21-28 días, y una segunda composición que contiene al menos un estrógeno y/o al menos una progestina, en una cantidad predeterminada mayor que la cantidad de la primera composición, y que comprende una secuencia mono o multifásica de dosificaciones farmacéuticas.
UY28631A 2003-11-26 2004-11-23 Uso extendido de combinación que comprende estrógenos y progestinas. UY28631A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03090405A EP1535618A1 (en) 2003-11-26 2003-11-26 Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions

Publications (1)

Publication Number Publication Date
UY28631A1 true UY28631A1 (es) 2005-06-30

Family

ID=34443011

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28631A UY28631A1 (es) 2003-11-26 2004-11-23 Uso extendido de combinación que comprende estrógenos y progestinas.

Country Status (22)

Country Link
US (1) US20080234240A1 (es)
EP (3) EP1535618A1 (es)
JP (1) JP2007512291A (es)
KR (1) KR20060126671A (es)
CN (1) CN1905885A (es)
AR (1) AR046671A1 (es)
AU (1) AU2004292778A1 (es)
BR (1) BRPI0416924A (es)
CA (1) CA2547051A1 (es)
CR (1) CR8450A (es)
EA (1) EA200600964A1 (es)
EC (1) ECSP066674A (es)
GT (1) GT200400242A (es)
IL (1) IL175858A0 (es)
NO (1) NO20062945L (es)
PA (1) PA8618301A1 (es)
PE (1) PE20051038A1 (es)
RS (1) RS20060348A (es)
TW (1) TW200529862A (es)
UY (1) UY28631A1 (es)
WO (1) WO2005051400A1 (es)
ZA (1) ZA200605224B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
DE102004062182B4 (de) * 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
JP2009501722A (ja) * 2005-07-15 2009-01-22 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ドロスピレノン含有経皮用薬剤供給装置及びその供給方法
EP1774970A1 (de) * 2005-10-13 2007-04-18 Bayer Schering Pharma AG Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest
DE102005056527A1 (de) * 2005-11-25 2007-07-12 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
WO2008018872A1 (en) * 2006-08-10 2008-02-14 Drugtech Corporation Therapeutic methods of using estrogen compositions
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
CN104546870B (zh) * 2015-01-27 2018-01-12 唐凡兰 一种避孕药
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
NO3106148T3 (es) 2015-06-18 2018-08-11
WO2016203009A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
JP2018083806A (ja) * 2016-11-11 2018-05-31 持田製薬株式会社 月経困難症治療用組成物
UY38075A (es) * 2018-02-07 2019-10-01 Estetra Sprl Composiciones anticonceptivas con efectos cardiovasculares reducidos
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
CL2021001762A1 (es) * 2021-07-01 2022-01-21 Univ Pontificia Catolica Chile Uso del estetrol como tratamiento para la endometriosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3969502A (en) * 1972-04-14 1976-07-13 Schering Aktiengesellschaft Method for contraception by the administration of sequential contraceptive preparations
AU581486B2 (en) * 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
US5010070A (en) * 1987-06-15 1991-04-23 Warner-Lambert Company Graduated estrogen contraceptive
DK174724B1 (da) 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
HU214598B (hu) * 1987-09-24 1998-04-28 Jencap Research Ltd Eljárás fogamzásgátló és hormonterápiához alkalmazható, ösztrogént és progesztint tartalmazó gyógyszerkészítmények előállítására
US5276022A (en) * 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
DE19549264A1 (de) * 1995-12-23 1997-06-26 Schering Ag Verfahren und Kit zur Kontrazeption
AU4043597A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen
US6028064A (en) * 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
AU9028098A (en) 1997-08-27 1999-03-16 Ortho Pharmaceutical Corporation Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
WO2003006027A1 (en) * 2001-07-13 2003-01-23 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
HU230759B1 (hu) 2001-12-05 2018-03-28 Teva Women's Health, Inc. Teherbeesés megakadályozására és menstruációs tünetek enyhítésére vagy kiküszöbölésére alkalmas orális készítmények

Also Published As

Publication number Publication date
NO20062945L (no) 2006-08-23
BRPI0416924A (pt) 2007-01-16
ECSP066674A (es) 2006-10-25
EP2044942A1 (en) 2009-04-08
TW200529862A (en) 2005-09-16
EA200600964A1 (ru) 2006-10-27
JP2007512291A (ja) 2007-05-17
CN1905885A (zh) 2007-01-31
AU2004292778A1 (en) 2005-06-09
AR046671A1 (es) 2005-12-14
RS20060348A (en) 2008-08-07
ZA200605224B (en) 2009-10-28
IL175858A0 (en) 2006-10-05
KR20060126671A (ko) 2006-12-08
CA2547051A1 (en) 2005-06-09
WO2005051400A1 (en) 2005-06-09
US20080234240A1 (en) 2008-09-25
CR8450A (es) 2007-06-06
EP1689409A1 (en) 2006-08-16
GT200400242A (es) 2006-01-18
PA8618301A1 (es) 2006-05-16
EP1535618A1 (en) 2005-06-01
PE20051038A1 (es) 2006-02-08

Similar Documents

Publication Publication Date Title
ECSP066674A (es) Uso extendido de combinación que comprende estrógenos y progestinas
CR10732A (es) Uso de valerato de estradiol o 17 b- estradiol en combinacion con dienogest en una terapia oral para mantener y / o incrementar la libido femenina
BR9915285A (pt) Composição farmacêutica para liberação modificada de um sensitivador de insulina e um outro agente antidiabético
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
ATE453391T1 (de) Östrogene mittel enthaltende arzneizusammensetzungen
CY1108093T1 (el) Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη
AR021981A1 (es) Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero
CR7022A (es) Productos esteroides hormonales y metodos para su preparacion
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
BRPI0214716B8 (pt) kit, preparos, e uso de estrogênio e progestina na fabricação de um medicamento para uso na prevenção de gravidez
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
BR0108738A (pt) Formulações anestésicas
BR9915215A (pt) Composição farmacêutica para liberação modificada de sensibilizador de insulina
ES2133003T3 (es) Utilizacion de al menos un glicol como agente de solubilizacion de la melatonina en agua y composiciones que los contienen.
BR0111051A (pt) Produto farmacêutico e dose farmacêutica diária para administração a um paciente, regime de dose prover um efeito anti-androgênico e um efeito anti-estrogênico em um paciente, uso de um composto e de tamoxifeno ou de um sal ou solvato farmaceuticamente aceitável destes, e, método para prover um efeito anti-androgênico em um paciente
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
PT1318820E (pt) Medicamento contendo xenon em concentracoes subanestesicas para utilizacao como agente cardiovascular
CY1112542T1 (el) Χρηση ενος οιστρογονου για τη βιομηχανικη κατασκευη μιας συνθεσης που περιεχει οιστρογονο για τη θεραπεια ατροφικης κολπιτιδας
AR043013A1 (es) Composicion farmaceutica destinada al tratamiento de la endometriosis
PE20070555A1 (es) Uso de valerato de estradiol en combinacion con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepcion oral
FR2839450B1 (fr) Preparation medicamenteuse notamment pour le traitement des hernies discales
DK1112066T3 (da) Anvendelse af methoxymorpholino doxorubicin til behandlingen af en levertumor
PE20000887A1 (es) Equipo anticonceptivo de tipo "solo progestageno" que permite un buen control del ciclo
AR031104A1 (es) Composicion farmaceutica que comprende un carboxialquileter y un agente antihipertensivo, primera composicion para su uso con una segunda composicion que comprenden un agente antihipertensivo y un carboxialquileter respectivamente, equipo que comprende un carboxialquileter y un agente antihipertensi

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150528